Skip to main content
SpringerLink
Log in

Effect of monthly ibandronate on hip structural geometry in men with low bone density

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

Hip structural analysis (HSA) performed in a subset of participants from the STudy Researching Osteoporosis iN Guys (STRONG) demonstrated that 1 year of ibandronate treatment was associated with a significant improvement in some but not all parameters of hip geometry relative to placebo in men with low bone density.

Introduction

HSA was performed on dual-energy X-ray absorptiometry (DXA) images in a subset of participants from the STRONG to examine the impact of monthly ibandronate on geometric properties of the hip in men with low bone density.

Methods

This prespecified subgroup analysis evaluated men in the intent-to-treat population of STRONG with baseline and 12-month DXA data. Cross-sectional geometric parameters of the femoral shaft (FS), intertrochanter region (IT), and narrow neck (NN) were calculated from femoral DXA scans. All analyses were exploratory. Treatment differences were evaluated using analysis of covariance, which adjusted for baseline parameter value, testosterone level, and treatment.

Results

HSA was performed on DXA scans from 89 men (34 placebo; 55 monthly ibandronate). Significant increases in average cortical thickness and cross-sectional area and decreases (i.e., improvements) in the buckling ratio were observed at the FS and IT at 12 months for ibandronate-treated men compared with placebo-treated men. No significant differences were observed between ibandronate and placebo for any NN HSA parameters.

Conclusions

One year of ibandronate treatment was associated with a significant improvement in some but not all parameters of hip geometry relative to placebo in men with low bone density, suggesting that ibandronate may improve resistance to axial compressive forces and bending forces at the hip.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Campion JM, Maricic MJ (2003) Osteoporosis in men. Am Fam Physician 67:1521–1526

    PubMed  Google Scholar 

  2. National Osteoporosis Foundation (2008) Fast facts on osteoporosis. Web site of the National Osteoporosis Foundation. http://www.nof.org/osteoporosis/diseasefacts.htm#top. Accessed September 8, 2009

  3. Fransen M, Woodward M, Norton R, Robinson E, Butler M, Campbell AJ (2002) Excess mortality or institutionalization after hip fracture: men are at greater risk than women. J Am Geriatr Soc 50:685–690

    Article  PubMed  Google Scholar 

  4. Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B (2010) Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing 39:203–209

    Article  PubMed  Google Scholar 

  5. Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G (2010) Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46:970–976

    Article  PubMed  CAS  Google Scholar 

  6. Cummings SR, Cawthon PM, Ensrud KE, Cauley JA, Fink HA, Orwoll ES (2006) BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 21:1550–1556

    Article  PubMed  Google Scholar 

  7. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194

    Article  PubMed  Google Scholar 

  8. Garnero P, Delmas PD (2004) Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 4:50–63

    PubMed  CAS  Google Scholar 

  9. Wachter NJ, Augat P, Krischak GD, Sarkar MR, Mentzel M, Kinzl L, Claes L (2001) Prediction of strength of cortical bone in vitro by microcomputed tomography. Clin Biomech Bristol Avon 16:252–256

    Article  CAS  Google Scholar 

  10. Wachter NJ, Krischak GD, Mentzel M, Sarkar MR, Ebinger T, Kinzl L, Claes L, Augat P (2002) Correlation of bone mineral density with strength and microstructural parameters of cortical bone in vitro. Bone 31:90–95

    Article  PubMed  CAS  Google Scholar 

  11. Silverman SL, Cummings SR, Watts NB (2008) Recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). J Bone Miner Res 23:159–165

    Article  PubMed  Google Scholar 

  12. Bonnick SL (2007) HSA: beyond BMD with DXA. Bone 41:S9–S12

    PubMed  Google Scholar 

  13. Rubin CD (2005) Emerging concepts in osteoporosis and bone strength. Curr Med Res Opin 21:1049–1056

    Article  PubMed  Google Scholar 

  14. Pulkkinen P, Partanen J, Jalovaara P, Jamsa T (2004) Combination of bone mineral density and upper femur geometry improves the prediction of hip fracture. Osteoporos Int 15:274–280

    Article  PubMed  Google Scholar 

  15. Bouxsein ML (2004) Non-invasive measurements of bone strength: promise and peril. J Musculoskelet Neuronal Interact 4:404–405

    PubMed  CAS  Google Scholar 

  16. Lewiecki EM, Keaveny TM, Kopperdahl DL, Genant HK, Engelke K, Fuerst T, Kivitz A, Davies RY, Fitzpatrick LA (2009) Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 94:171–180

    Article  PubMed  CAS  Google Scholar 

  17. Beck TJ, Looker AC, Ruff CB, Sievanen H, Wahner HW (2000) Structural trends in the aging femoral neck and proximal shaft: analysis of the Third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data. J Bone Miner Res 15:2297–2304

    Article  PubMed  CAS  Google Scholar 

  18. Epstein S (2007) Is cortical bone hip? What determines cortical bone properties? Bone 41:S3–S8

    Article  PubMed  Google Scholar 

  19. Russo CR, Lauretani F, Seeman E, Bartali B, Bandinelli S, Di Iorio A, Guralnik J, Ferrucci L (2006) Structural adaptations to bone loss in aging men and women. Bone 38:112–118

    Article  PubMed  Google Scholar 

  20. Orwoll ES, Klein RF (1995) Osteoporosis in men. Endocr Rev 16:87–116

    PubMed  CAS  Google Scholar 

  21. Fuerst T, Beck TJ, Gaither K, Kothari M, Genant HK (2006) Effect of oral ibandronate on hip structure: results from the BONE study (abstract). J Bone Miner Res 21:S287

    Google Scholar 

  22. Beck T (2003) Measuring the structural strength of bones with dual-energy X-ray absorptiometry: principles, technical limitations, and future possibilities. Osteoporos Int 14(Suppl 5):S81–S88

    Article  PubMed  Google Scholar 

  23. Bonnick SL, Beck TJ, Cosman F, Hochberg MC, Wang H, de Papp AE (2009) DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass. Osteoporos Int 20:911–921

    Article  PubMed  CAS  Google Scholar 

  24. Prevrhal S, Shepherd JA, Faulkner KG, Gaither KW, Black DM, Lang TF (2008) Comparison of DXA hip structural analysis with volumetric QCT. J Clin Densitom 11:232–236

    Article  PubMed  Google Scholar 

  25. Beck T (2002) Hip structural analysis (HSA) program (BMD and structural geometry methodology) as used to create NHANES III dataset. CDC electronic file. ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Datasets/NHANES/NHANESIII/17a/hip_methods.pdf. Accessed February 18, 2010

  26. Melton LJ 3rd, Beck TJ, Amin S, Khosla S, Achenbach SJ, Oberg AL, Riggs BL (2005) Contributions of bone density and structure to fracture risk assessment in men and women. Osteoporos Int 16:460–467

    Article  PubMed  Google Scholar 

  27. Greenspan SL, Beck TJ, Resnick NM, Bhattacharya R, Parker RA (2005) Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. J Bone Miner Res 20:1525–1532

    Article  PubMed  CAS  Google Scholar 

  28. Beck TJ, Cauley JA, de Papp AE, Wehren LE, Baran DT (2006) Alendronate improves the structural geometry of the proximal femur in postmenopausal osteoporotic women (abstract). Osteoporos Int 17:S73

    Google Scholar 

  29. Bonnick SL, Beck TJ, Cosman F, Hochberg MC, Baran D, Shah A, Wang H, Wehren LE, de Papp AE (2006) Comparison of effects of alendronate versus risedronate on the structural geometry of the hip: an analysis of the US Fosamax Actonel Comparison Trial (FACT) extension data (abstract). J Bone Miner Res 21:S180

    Google Scholar 

  30. van Londen GJ, Perera S, Vujevich KT, Sereika SM, Bhattacharya R, Greenspan SL (2008) Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women. Bone 43:274–278

    Article  PubMed  Google Scholar 

  31. Uusi-Rasi K, Beck TJ, Semanick LM, Daphtary MM, Crans GG, Desaiah D, Harper KD (2006) Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int 17:575–586

    Article  PubMed  CAS  Google Scholar 

  32. Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16:510–516

    Article  PubMed  CAS  Google Scholar 

  33. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17

    Article  PubMed  CAS  Google Scholar 

  34. Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ (2005) Effects of teriparatide [rhPTH (1–34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36:948–958

    Article  PubMed  CAS  Google Scholar 

  35. Beck TJ, Lewiecki EM, Miller PD, Felsenberg D, Liu Y, Ding B, Libanati C (2008) Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom 11:351–359

    Article  PubMed  Google Scholar 

  36. Yates LB, Karasik D, Beck TJ, Cupples LA, Kiel DP (2007) Hip structural geometry in old and old-old age: similarities and differences between men and women. Bone 41:722–732

    Article  PubMed  Google Scholar 

  37. Kaptoge S, Dalzell N, Loveridge N, Beck TJ, Khaw KT, Reeve J (2003) Effects of gender, anthropometric variables, and aging on the evolution of hip strength in men and women aged over 65. Bone 32:561–570

    Article  PubMed  Google Scholar 

  38. Beck TJ (2007) Extending DXA beyond bone mineral density: understanding hip structure analysis. Curr Osteoporos Rep 5:49–55

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported and funded by Genentech and GlaxoSmithKline. The authors would like to acknowledge the writing assistance of Rebecca Jarvis, PhD, and Kim Coleman Healy, PhD, of Envision Scientific Solutions, Southport, CT, in the preparation of this manuscript.

Conflicts of Interest

Dr. Genant is a Board of Directors member and stockholder of Synarc, Inc. and is an advisory board and speakers’ bureau member (receiving honoraria) for GlaxoSmithKline, Merck, Lilly, Amgen, Roche, Genentech, Pfizer, Servier, and Bristol-Myers-Squibb.

Dr. Lewiecki has received grant/research support from Amgen, Merck, Eli Lilly, Novartis, Warner Chilcott, and Genentech. He has served as a consultant, advisory board member, speakers’ bureau participant, or given presentations at sponsored speaking events for Amgen, Eli Lilly, Novartis, and Genentech.

Dr. Fuerst has no disclosures.

Dr. Fries is an employee of GlaxoSmithKline.

Author information

Authors and Affiliations

  1. University of California, San Francisco, CA, USA

    H. K. Genant

  2. Synarc, Inc., San Francisco, CA, USA

    H. K. Genant & T. Fuerst

  3. New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA

    E. M. Lewiecki

  4. GlaxoSmithKline, King of Prussia, PA, USA

    M. Fries

  5. Radiology, Orthopaedic Surgery, Medicine and Epidemiology, University of California San Francisco, San Francisco, CA, 94143-1250, USA

    H. K. Genant

Authors
  1. H. K. Genant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. M. Lewiecki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Fuerst
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Fries
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. K. Genant.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Genant, H.K., Lewiecki, E.M., Fuerst, T. et al. Effect of monthly ibandronate on hip structural geometry in men with low bone density. Osteoporos Int 23, 257–265 (2012). https://doi.org/10.1007/s00198-011-1732-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-011-1732-9

Keywords

Search

Navigation